Trials / Completed
CompletedNCT04979910
Targeting IL-17A for Treatment-Resistant Depression
An Experimental Therapeutics Study of a Monoclonal Antibody Against Interleukin 17A in Patients With Treatment-Resistant Depression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Icahn School of Medicine at Mount Sinai · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
Detailed description
In the proposed study n=20 adult individuals with TRD will be treated with ixekizumab for 4 weeks. Participants will complete screening procedures, body fluid analyses and brain imaging before and after treatment with ixekizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | a monoclonal antibody (mAb) against interleukin 17A (IL-17A) |
Timeline
- Start date
- 2021-08-27
- Primary completion
- 2024-04-12
- Completion
- 2024-04-12
- First posted
- 2021-07-28
- Last updated
- 2025-05-20
- Results posted
- 2025-05-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04979910. Inclusion in this directory is not an endorsement.